特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

C型肝炎ウイルス (HCV) 外膜タンパク質E2:パイプライン製品の分析

Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H1 2020

発行 Global Markets Direct 商品コード 364864
出版日 ページ情報 英文 34 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.59円で換算しております。
C型肝炎ウイルス (HCV) 外膜タンパク質E2:パイプライン製品の分析 Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H1 2020
出版日: 2020年05月30日 ページ情報: 英文 34 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

当レポートでは、C型肝炎ウイルス (HCV) 外膜タンパク質E2を標的とした治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

C型肝炎ウイルス (HCV) 外膜タンパク質E2 概要

治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療領域別
  • 開発中の製品:症状別

パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/研究機関で開発中の製品

治療薬の評価

  • 単剤併/用治療薬の場合
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Integrated BioTherapeutics, Inc.

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

主なニュースおよびプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Ennaid Therapeutics LLC, H1 2020
  • Pipeline by Integrated BioTherapeutics Inc, H1 2020
  • Pipeline by Toray Industries Inc, H1 2020
  • Dormant Projects, H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
目次
Product Code: GMDHC2431TDB

Summary:

Hepatitis C Virus Envelope Protein E2 pipeline Target constitutes close to 9 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The latest report Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H1 2020, outlays comprehensive information on the Hepatitis C Virus Envelope Protein E2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Hepatitis C Virus Envelope Protein E2 - E2 is a viral structural protein found in the hepatitis C virus. It is present on the viral membrane and functions as a host receptor binding protein mediating entry into host cells. It is an important target for the design of entry inhibitors and vaccine immunogens. The molecules developed by companies in Preclinical stages are 3 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 2 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Hepatitis C.

Furthermore, this report also reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Hepatitis C Virus Envelope Protein E2
  • The report reviews Hepatitis C Virus Envelope Protein E2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics and enlists all their major and minor projects
  • The report assesses Hepatitis C Virus Envelope Protein E2 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Hepatitis C Virus Envelope Protein E2 targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Hepatitis C Virus Envelope Protein E2
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hepatitis C Virus Envelope Protein E2 development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hepatitis C Virus Envelope Protein E2 - Overview
    • Hepatitis C Virus Envelope Protein E2 - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Hepatitis C Virus Envelope Protein E2 - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hepatitis C Virus Envelope Protein E2 - Companies Involved in Therapeutics Development
    • Ennaid Therapeutics LLC
    • Integrated BioTherapeutics Inc
    • Toray Industries Inc
  • Hepatitis C Virus Envelope Protein E2 - Drug Profiles
    • CIGB-230 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis C (strain H77) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hepatitis C Virus Envelope Protein E2 - Dormant Products
  • Hepatitis C Virus Envelope Protein E2 - Discontinued Products
  • Hepatitis C Virus Envelope Protein E2 - Product Development Milestones
    • Featured News & Press Releases
      • Jun 10, 2013: IBT and Stanford Awarded STTR
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer